-
China’s Triastek and Germany’s BioNTech Join Forces for 3D Printed Oral Therapeutics
•
Triastek Inc., a China-based pharmaceutical company specializing in 3D printing technology, has entered into a strategic partnership with Germany’s BioNTech SE (NASDAQ: BNTX), a leading figure in the biopharmaceutical industry. This collaboration aims to leverage Triastek’s cutting-edge 3D drug printing capabilities to develop a breakthrough oral preparation designed to address…
-
Triastek Partners with Kangerjia to Develop 3D-Printed Modified Drugs for Sleep Disorders
•
Triastek Inc., a China-based pharmaceutical-focused 3D printing company, has entered into a partnership with fellow Chinese firm Nanjing Kangerjia Medical Technology Co., Ltd to collaboratively develop modified drugs aimed at treating sleep disorders. This strategic alliance combines Triastek’s expertise in 3D printing technology with Kangerjia’s commercialization experience in the field…
-
Triastek Partners with BASF to Advance 3D Printing Materials for Pharmaceuticals
•
China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with German giant BASF SE. This collaboration aims to explore and enhance research and development of new materials for application in drug 3D printing. Financial details of the partnership have not been disclosed. Triastek utilizes a…
-
Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline
•
China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured RMB 150 million (USD 20.5 million) in a pre-Series C financing round. The investment, led by Guoxin Investment, includes participation from Gold Mine Multi-Family Office and Zheng Xiaodong, chairman of Shanghai Tofflon Sci &Tech Co.,…
